Deep Vein Thrombosis Prophylaxis in Trauma Patients by Toker, Serdar et al.
Hindawi Publishing Corporation
Thrombosis
Volume 2011, Article ID 505373, 11 pages
doi:10.1155/2011/505373
Review Article
Deep VeinThrombosisProphylaxis inTrauma Patients
SerdarToker,1 David J. Hak,2 and StevenJ.Morgan2
1Orthopaedic Trauma Research, Denver Health, University of Colorado, 777 Bannock Street MC 0188, Denver, CO 80204, USA
2Denver Health, University of Colorado, 777 Bannock Street MC 0188, Denver, CO 80204, USA
Correspondence should be addressed to Serdar Toker, tokerserdar@hotmail.com
Received 1 November 2010; Accepted 10 March 2011
Academic Editor: Omer Iqbal
Copyright © 2011 Serdar Toker et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are known collectively as venous thromboembolism (VTE). Venous
thromboembolic events are common and potentially life-threatening complications following trauma with an incidence of 5 to
63%. DVT prophylaxis is essential in the management of trauma patients. Currently, the optimal VTE prophylaxis strategy for
trauma patients is unknown. Traditionally, pelvic and lower extremity fractures, head injury, and prolonged immobilization have
been considered risk factors for VTE; however it is unclear which combinationof risk factors deﬁnes a high-risk group. Modalities
available for trauma patient thromboprophylaxis are classiﬁed into pharmacologic anticoagulation, mechanical prophylaxis, and
inferior vena cava (IVC) ﬁlters. The available pharmacologic agents include low-dose heparin (LDH), low molecular weight
heparin (LMWH), and factor Xa inhibitors. Mechanical prophylaxis methods include graduated compression stockings (GCSs),
pneumatic compression devices (PCDs), and A-V foot pumps. IVCs are traditionally used in high risk patients in whom
pharmacologicalprophylaxis is contraindicated. Both EAST and ACCP guidelines recommend primary use of LMWHs in trauma
patients; however there are still controversies regarding the deﬁnitive VTE prophylaxis in trauma patients. Large randomized
prospective clinicalstudies wouldbe required to provide level I evidence to deﬁne the optimalVTE prophylaxisin traumapatients.
1.Introduction
Deep vein thrombosis (DVT) and pulmonary embolism
(PE), known collectively as venous thromboembolism
(VTE), aﬀect an estimated 900,000 people in the U.S. each
year resulting in several hundred thousand hospitalizations
and about 300,000 deaths [1]. About two-thirds of episodes
manifest as DVT and one-third as PE with or without
DVT [2, 3]. In general surgical patients without prophylaxis
against VTE, the incidence of DVT has been reported to be
as high as 30%, with an associated fatality risk of 1% [4].
Venous thromboembolic events are also common and
potentially life-threatening complications after traumatic in-
jury [5–10]. Coagulopathy is present immediately at admis-
sion in 25% of trauma patients, and it is associated with a
5-fold increase in mortality [11]. Sevitt and Gallagher’s [12]
autopsy study of 125 patients revealed a 65% incidence of
DVT and 16% incidence of PE. The incidence of DVT varies
from5to 63%intraumapatientsdependingonpatient’srisk
factors, modality of prophylaxis, and methods of detection
[13, 14]. A general population study that followed 21,680
persons for occurrence of venous thrombosis over 7.6 years
demonstrated that trauma was only present in 6%, revealing
a relatively low potential number of cases globally that could
be avoided with prophylaxis in this setting, while cancer
was present in 48% and surgery was present in 42% [14].
Shackford et al. [15] also reported of an incidence of 7%
in the high-risk trauma patient. Nevertheless two factors
suggest an increasing incidence of thromboembolism after
trauma. First, the average age of the population increases
[16]; second, improvements in several ﬁelds have resulted in
the survival of more seriously injured patients who are at
high risk for VTE [16, 17]. Therefore VTE prophylaxis is
warranted for patients sustaining traumatic injuries [9, 13,
18–20]. Without thromboprophylaxis, the rate of venous
thrombosis and subsequent PE is substantial [18].
The optimal VTE prophylaxis strategy for trauma pa-
tients with a contraindication to pharmacological prophy-
laxisbecauseofariskofbleedingisunknown[6–9].Methods
of prophylaxis and detection continue to improve; however,2 Thrombosis
a signiﬁcant proportion of patients still develop VTE [8, 21].
In addition, the diﬃculty in determining optimal treatment
is further complicated by the presence of occult DVTs at
a 60% rate of occurrence [17, 22]. In this paper we aim
to investigate the various approaches for VTE prophylaxis
in trauma patients and report what appears to be the best
practice for optimal VTE prophylaxis in trauma patients.
A detailed literature search was completed to extrapolate
articles that described DVT and DVT prophylaxis. Speciﬁc
search terms used included DVT, risk factors, trauma,
guidelines, and prophylaxis.
2.RiskFactorsforDVT inTraumaPatients
Numerous diﬀerent factors have been cited in the literature
as posing a high risk for VTE in trauma patients. Several
prospective studies have examined the risk of DVT after
trauma [9]. Traditionally, pelvic and lower extremity frac-
tures, head injury, and prolonged immobilization have been
considered risk factors for VTE [8].
Tissue factor, which is abundant in the brain, plays an
important role in initiating coagulopathy following head
trauma. Early coagulopathy after traumatic brain injury
has been thought to be the result of the injury-mediated
local release of TF which activates the extrinsic pathway of
blood coagulation [23]. However, Geerts et al. [9]i nt h e i r
prospective clinical trial found that major head injury was
not associated with DVT. They also did not ﬁnd signiﬁcant
association between DVT and sex, injury severity score
(ISS), pelvic fracture, and amount of blood transfused. They
reported that the independent predictors of DVT were age,
bloodtransfusion, surgery, fracture ofthefemurortibia,and
spinal cord injury. According to this study the presence of
bloodtransfusion was important, buttheamount oftransfu-
sion was not associated with DVT. Kudsk et al. [17]a l s od i d
not ﬁnd an increase of DVT incidence with injury severity
score but they found that it increased with increasing age.
The eﬀect of blood transfusion alone on DVT develop-
ment has also been investigated. In a retrospective cohort
study,Spinellaetal.[24]foundthatintraumapatientstrans-
fused 5 or more units of RBCs, DVT and in-hospital
mortality was increased with the transfusion of old RBCs
when compared with a group of patients similar severity of
injury who were transfused RBCs of decreased storage age.
Knudson et al. [3] in an analysis of 450,375 patients in
theAmericanCollegeofSurgeons(ACS)National DataBank
found six factors to be independently signiﬁcant for VTE in
traumapatients.Thesefactorswereage≥40,lowerextremity
fracture with AIS (abbreviated injury score) ≥ 3, ventilator
days > 3, head injury with AIS ≥ 3, venous injury, and a
major operative procedure.
Patients with acute spinal cord injury (SCI)) and paraly-
sis are at considerablerisk for developingDVT [25–27]. Fujii
et al. [25] using radioﬁbrinogen uptake test in a group of
patients with SCI found the overall incidence of DVT to be
as higher as 57%.
In general, older age increases risk; however, the speciﬁc
age at which risk increases is unclear [8]. Selby et al. [10]i n
Table 1: Individual risk factors and points allotted to calculate the
RAP score.
Underlying condition Points
Obesity 2
Malignancy 2
Abnormalcoagulation 2
History of thromboembolism 3
Iatrogenic factors
Femoral venous line 2
Transfusion > 4u n i t s 2
Operation > 2h o u r s 2
Major venous repair 3
Injury-related factors
Chest AIS > 22
Abdomen AIS > 22
Head AIS > 22
Spinal fractures 3
Glascow coma score < 83
Severe lower extremity fracture 4
Pelvic fracture 4
Spinal cord injury 4
Age (years)
≥40, <60 2
≥60, <75 3
≥75 4
their prospective cohort study found that the increasing age
was thesingle most important independentpredictor ofVTE
in trauma patients. The reasons for an increased thrombosis
risk with ageare not understood,butmay relate toincreasing
presence of other illnesses predisposing to thrombosis, to
increase in coagulation potential, or some combination of
these [2].
Despite these numerous risk factors associated with the
development of DVT, it is unclear which individual or
combination of risk factors deﬁnes a high-risk group [22].
A risk assessment proﬁle (RAP) score was developed by
Greenﬁeld et al. [28]( Table 1). The study by Gearhart et al.
[22] supported the results of this pilot study which showed
patients with a RAP score of 5 or more were 3 times more
likely to experience the development of VTE than patients
with a RAP score of less than 5.
3.DVT Mechanism in Trauma
For thrombus formation, three important factors, blood
ﬂow, blood component and blood vessels, have been recog-
nized as Virchow’s triad [29]. Major trauma often precip-
itates one or all of these risk factors in Virchow’s triad of
hypercoagulability,endothelialinjury,andvenousstasis[20].
According to Hak [16], trauma patients often have all three
of these factors leading to a high risk of thromboembolism.
Direct injury to blood vesselscan cause intimal damage lead-
ing to thrombosis and prolonged bed rest, immobilization,
hypoperfusion, and paralysis, all promote venous stasis [8].Thrombosis 3
DecreasedlevelsofantithrombinIII[30,31]andsuppression
of ﬁbrinolysis [32, 33] may lead the trauma patient to
become hypercoagulable. In a recent study, Okamura et al.
[34] found that plasma levels of D-dimer and soluble ﬁbrin
monomer complex was higher than normal in hip fracture
patients. Peetz et al. [35] also showed more increased levels
of D-dimer in high-risk orthopaedic surgery patients when
compared with low-risk group.
Several studies have established that thromboplastin
(Tissue factor; TF) and markers of thrombin generation
increase after trauma [36–38] and that levels of natural anti-
coagulants such as antithrombin (AT), protein C (PC) and
protein S (PS) are reduced [31, 37]. Selby et al. [10]c o n -
cluded that major trauma leads to signiﬁcantly increased
and persistent thrombin with disruption of its regulation.
Increased severity of hypoperfusion was associated with an
increase in plasma thrombomodulin and a reduction in
protein C levels. This suggests that acute coagulopathy is due
to systemic anticoagulation through activation of the protein
Cp a t h w a y[ 39].
Besides consumption of clotting factors, acidosis and
hypothermia leading to reduced activity [39], and dilution
from intravenous ﬂuids and packed cell administration [39,
40]arealsoacceptedcausesoftraumaticcoagulopathy.How-
ever regarding the early phase of coagulopathy in trauma,
Brohi et al. [39] stated that acute traumatic coagulopathy is
not due to coagulation factor consumption or dysfunction
because of acidosis, moderate hypothermia, or dilution.
Theystatedthatshockitselfisassociated withacoagulopathy
that is due to the systemic activation of anticoagulant and
ﬁbrinolytic pathways.
Immobilityisalsoarecognized causeofVTE.Immobility
due to paralysis is one of the major contributing factors for
the development of DVT in patients with trauma to the
spinal cord [25]. The lackof pumping action ofthe contract-
ing muscles results in blood ﬂow reduction and pooling of
bloodintheintramuscularsinuses ofthecalf,leadingtoDVT
[41]. Increased hematocrits, elevated ﬁbrinogen, and von
Willebrand factor macromolecular complex levels increase
bloodviscosity [42,43],andthismayfurtherinﬂuenceblood
ﬂow [44]. Decreased blood ﬂow could lead to endothelial
damage, local accumulation of activation products of coag-
ulation, and local decrease in inhibitor levels, all increasing
coagulability of the blood [25]. According to Meissner et al.
[36], associations with immobilization and obesity suggest
that VTE after injury is a systemic hypercoagulable disorder
with local manifestations of thrombosis related to lower
extremity stasis.
4.ProphylaxisforDVT inTraumaPatients
Most methods of VTE prophylaxis that are eﬀective in non-
trauma patients are ineﬀective for multiply injured patients
[8, 16] because the factors leading to thrombosis likely
develop immediately after the injury, before administration
ofany typeofprophylactic therapy is possible [16,20]. Addi-
tionally, contraindications arising from associated injuries
often limit the potential options for prophylaxis in patients
with trauma [16]. However it is reported that without
thromboprophylaxis overall DVT rates exceed 50% [9, 17,
45].
Multiple studies have demonstrated the eﬃcacy of DVT
prophylaxis [3, 9, 22, 46, 47], and treatment algorithms
have been established (Figure 1). However deﬁnitive ran-
domized controlled clinical studies of prophylactic measures
in trauma patients with multiple injuries are limited [3]
since this heterogenous population necessitates a very large
study size, which rarely has beenachieved in previousstudies
[16]. Thus controversy exists as to the optimal method of
prophylaxisinpatientsfollowing trauma[16,46,47].Modal-
ities available for trauma patient thromboprophylaxis are
classiﬁed into pharmacologic anticoagulation, mechanical
prophylaxis, and inferior vena cava (IVC) ﬁlters [18, 48].
5.PharmacologicProphylaxis
5.1. Low-Dose Heparin (LDH). Ar e v i e wo ft h eg e n e r a l
surgical literature shows that the incidence of DVT can
be diminished by as much as 20% to 40% with minidose
prophylactic heparin [49]. Low-dose heparin (LDH) given
in doses of 5,000 units subcutaneously two or three times
daily, represents one pharmacologic treatment modality for
prophylaxis against DVT/PE [50]. Ruiz et al. [20]p o i n t i n g
outthatthesedatahavesincebeenappliedtotraumapatients
without substantiation [17], studied on 100 consecutive
patients with multiple trauma in order to determine the
eﬃcacyoflow-doseheparinandfoundthatitdidnotprovide
adequate protection in trauma patients with an ISS > 10.
Ganzer et al. [51] also concluded that for the prophylaxis
of thromboembolic complications especially in the high-
risk areas of orthopedics and trauma surgery, unfractioned
standard heparin (UFH) is insuﬃciently eﬀective and asso-
ciated with a high risk of side-eﬀects. Geerts et al. [52]i na
randomized, double blind, prospective trial comparing LDH
with LMWHfoundthatLDHwas signiﬁcantlyinsuﬃcientin
DVTprevention.InsomeotherstudiescomparingLDHwith
no prophylaxis [3, 15, 53–56], no signiﬁcant diﬀerence was
reported. Despitethe similar resultsshowing theineﬃcacy of
LDH in all these studies, a recent study by Arnold et al. [57]
showed comparable rates of DVT in trauma patients receiv-
ing standard-dose 30mg bid enoxaparin versus 5000U three
times a day heparin. The authors concluded that in trauma
patients, subcutaneous heparin dosed three times a day may
be as eﬀective as standard-dose 30mg bid enoxaparin for
VTE prophylaxis without increased complications, and this
was associated with signiﬁcant pharmaceutical cost savings.
5.2. Low Molecular Weight Heparin (LMWH). LMWHs are
generated from the chemical depolymerization of unfrac-
tioned heparin (UH). This reduces their size, charge, and
weight. Secondary to their smaller size, LMWHs have signif-
icantly greater activity towards factor Xa than UHs [58].
LMWHs gained popularity as prophylactic agents for
VTE in early 1990s [59] and have emerged in the late 1990s
as themost (oronly)eﬀectivemethod ofDVTprophylaxisin
trauma patients [8, 50]. Multiple studies have investigated4 Thrombosis
Obesity
Malignancy
Abnormal coagulation
Injury related factors
Chest AIS > 2
Abdomen AIS > 2
Head AIS > 2
Spinal fractures
GCS < 8
Severe lower extr. ftx.
Pelvic fracture
Spinal cord injury
Latrogenic factors
Femoral line
Transfusion > 4units
Operation > 2hours
Major venous repair
Underlying condition
Age (years)
>40, <60
60, <75
>75
Low risk RAP < 5
Contraindication to prophylactic
anticoagulation?
Enoxaparine 30mg sq bid
or dalteparin 5000IU
sq/day
Consider SCD
or foot pumps
Continued/prolonged contraindication to anticoagulation
Yes
No prophylactic theraphy required
Encourage early mobilization
Consider IVC ﬁlter
RAP score
History of thromboembolism
2
2
2
2
2
2
2
3
3
3
3
4
4
4
4
2
2
2
2 No
No
Yes
Reevaluate
High risk RAP ≥5
in 24–48hours
-
-
-
Figure 1: Algorithm for VTE prophylaxis [8].
theoptimalmethod ofprophylaxisforDVT,recognizing that
DVT and PE rates are lowered in trauma patients who are
treated with LMWH [46, 52, 60–63]. In 1990, Green et al.
[62], in a study of patients with spinal cord injury, found
that LMWH was safe and eﬀective for VTE prevention in
complete motor paralysis and was superior to subcutaneous
heparin. Inone ofthe most cited studiesonthis topic,Geerts
et al. [52] comparing LDH with LMWH found an incidence
of 44% and 31% (P = .014) of DVT, and 15% and 6%
(P = .012) of proximal DVT respectively. They concluded
that LMWH should be considered the method of choice for
the prophylaxis of trauma patients. In 1994 Knudson et al.
[60] showed that LMWH (enoxaparin 30mg bid) was safe
andeﬀectiveinpreventingDVTinhigh-risktraumapatients.
In 1998, American College of Chest Physcians (ACCP)
recommended DVT prophylaxis in multiple trauma patients
with LMWH for the ﬁrst time. In 2007, Cothren et al. [46]
in a prospective study including 6247 trauma patients found
that once-daily dosing of prophylactic LMWH dalteparin
was feasible, safe, and eﬀective in high-risk trauma patients
allowing to “operate through” systemic prophylaxis and
ensuring timely prophylaxis for brain-injured and multi-
system trauma patients. In a recent study, Sems et al. [64]
favored the protocol of early joint spanning external ﬁxation
with the concurrent use of LMWH in patients with high-
energylowerextremity trauma.Theyfounda2.1%incidence
of DVT on duplex ultrasound examination and concluded
that this incidence does not exceed historical controls.
There is a controversy in dosing of LMWHs. Some
authors [35, 59] suggested dose adjustment according to the
levels of D-Dimer in prevention of DVT in trauma patients.
[65] found no diﬀerence in the incidence of DVT between
the patients who received standard and body-weight-
adjusted dose of LMWH. However a recent study by Mali-
noski et al. [66] showed that standard dosing of enoxaparin
leads to low anti-Xa levels which are associated with a signif-
icant increase in the risk of DVT in half of surgical intensive
care unit (ICU) patients, and authors concluded that these
datasupportfuturestudiesusing adjusted-doseenoxaparine.
In severely injured patients, VTE remains a major cause
of potentially preventable death despite considerable pro-
phylactic eﬀorts particularly in those who are believed to
have contraindications to receiving a heparin drug [8, 21].
Because of the fact that safer and more eﬀective prophylactic
measuresareneededforhigh-risk traumapatients,searchfor
new solutions is ongoing.
5.3. Fondaparinux. Fondaparinux is a nonheparin drug and
the ﬁrst synthetic pentasaccharide selectively inhibiting
Factor Xa [21, 67, 68]. Alongwith its antithrombotic eﬃcacy
in preventing VTE after elective orthopaedic operations andThrombosis 5
in selected high-risk abdominal surgical patients [21], the
safetyoffondaparinux hasbeendocumentedinseveralPhase
II and III clinical trials [68]. Two studies were performed to
detect the eﬃcacy of fondaparinux in hip fracture surgery
[69, 70]. In the ﬁrst study by Eriksson et al. [69] in 2001,
a risk reduction of 56.4% was found in the fondaparinux
group versus enoxaparine group. The second study by the
same group in 2004 revealed a 1.4% incidence of DVT
following a hip fracture surgery [70]. Despite these studies,
Fondaparinux has never been used in trauma patients until
a pilot study was performed by Lu et al. [21] in 2009. In
this study, authors found a 4.6% overall incidence of DVT
and a 1.2% incidence of DVT in patients receiving fonda-
parinux. There were no episodes of pulmonary embolism,
thrombocytopenia,orbleedingattributabletofondaparinux.
Authorsconcludedthatthisagent appearsto oﬀerprotection
against VTE in high-risk trauma patients. Its once-daily
dosingregimen canimprovecomplianceand reducecostand
eliminate risk of heparin-induced thrombocytopenia. Asthis
is a pilot study with a lack of a control group and with a
relatively small size, further research on this agent is needed.
6.Mechanical Prophylaxis
Varioustypesofexternalcompressiondevicesareavailableto
provide DVT prophylaxis in the immobilized patient. These
devices include graduated compression stockings (GCS),
sequential pneumatic compression devices (PCDs), and
pneumatic plantar (A-V) foot pumps [16]. They function
by reducing the luminar diameter of a vein resulting in an
increase in venous ﬂow velocity, and they are commonly uti-
lized in trauma setting because of ease of use and inherently
low risk of associated bleeding [18].
6.1. Graduated Compression Stockings. GCSs are widely used
for prevention and treatment of DVT in nontrauma patients
[71–77]. In a recent systemic review of 18 randomised
clinical trials (RCTs), Sachdeva et al. [78] concluded that
GCSs are eﬀective in diminishing the risk of DVT in
hospitalized patients; however, these devices have not been
reported in the trauma population [18].
6.2. Pneumatic Compression Devices. PCDs for prophylaxis
against DVT has been studied and increasingly used in
trauma patients [53, 56, 79–81]. Despite the ﬁndings that
PCDs were comparable to the eﬀect of LDH in signiﬁcantly
lowering DVT incidence compared with controls with no
prophylaxis [56, 81] and despite the given same rate of
DVT for clinically injured patients prophylaxed with either
Sequental Compression Device (SCD), LDH, or a combi-
nation of these [79], a meta-analysis by Velmahos et al.
[56] showed that PCD oﬀered no beneﬁt over no prophy-
laxis. Kurtoglu et al. [82] also prospectively randomized
120 head/spinal traumatized patients for comparison of
IPC with LMWH as a prophylaxis modality against VTE.
Venous duplex color-ﬂow Doppler sonography of the lower
extremities was performed each week of hospitalization and
1 week after discharge. There was no statistically signiﬁcant
diﬀerence regarding a reduction in DVT, PE, or mortality
between groups (P = .04, P>. 05, P>. 05, resp.), and
they concluded that PCD can be used safely for prophylaxis
of VTE in head/spinal trauma patients.
Mechanical VTE prophylaxis by graduated compression
stockings or intermittent pneumatic compression provides
suboptimal protection, and its use is recommended only
in combination with LMWH prophylaxis [83]o rw h e n
anticoagulant DVT prophylaxis is contraindicated [18].
6.3. A-V Foot Pumps. In 1983, Gardner and Fox ﬁrst
described the physiologic pumping mechanism of the sole
of the foot and in 1990 Laverick demonstrated that arterio-
venous (A-V) foot pump increases venous blood ﬂow in
popliteal vein by 250% [50]. In a recent study by Pitto
and Young [76, 77], the authors found a 2.7% incidence
of DVT in a group of patients following total hip or total
knee arthroplasty. A-V foot pumps were studied in several
trauma patient groups, and their eﬃcacy was compared
with PCD and LMWH. Knudson et al. [84]f o u n dh i g h e r
rates of DVT with foot pumps when compared with PCD
and LMWH, and Anglen et al. [85] found an incidence of
4% of DVT with foot pumps and 0% with PCD. However,
Spain et al. [86] found no signiﬁcant diﬀerence in DVT
rates between the two groups, with PCDs at 7% and A-
V foot pumps at 3%. In a recent study by Stannard et al.
[87],enoxaparinetreatmentwascomparedwithenoxaparine
plus foot pumps treatment. The prevalence of deep-vein
thrombosis was 13.4% for enoxaparine group, and 8.7% for
enoxaparine plus foot pumps group. There were eleven large
or occlusive clots (prevalence, 11.3%) in enoxaparine group,
compared with only three (prevalence,2.9%) in enoxaparine
plus foot pumps group (P = .025). The prevalence of
pulmonary embolism was 2.1% in enoxaparine group and
0% in enoxaparine plus foot pumps group. The authors
concluded early mechanical prophylaxis with foot pumps
and the addition of enoxaparin on a delayed basis was a very
successful strategy for prophylaxis against venous throm-
boembolic disease following serious musculoskeletal injury.
7.Vena CavaFilters(VCFs)
The eﬀectiveness of a VCF in the prevention of pulmonary
embolism in patients with proximal DVT has been well
established. Traditionally, these ﬁlters have been placed in
patients with acute proximal DVT or a recent PE who
have either a contraindication to receive heparin, who had
bleeding during heparin treatment, or who have had a PE
despite anticoagulation [3]. Thus in trauma patients with
contraindications to chemoprophylaxis and mechanical pro-
phylaxis [18, 50], VCFs oﬀer one option to reduce morbidity
and mortality associated with embolism.
Unfortunately VCFsare not without risks and potentially
transient nature of the hypercoagulable states in the majority
of trauma patients has made this a less attractive option
[88]. However with concern about the ineﬀectiveness of
available VTE prophylaxis in injured patients, some authors
have advocated the placement of VCFs in high-risk patients6 Thrombosis
who have neither PE nor DVT [88–92]. This is certainly con-
troversial [55], however, a retrospective analysis of data from
the National Trauma Data Bank of the American College of
Surgeons by Shackford et al. [93] demonstrated that 6282
of 617,349 patients received a VCF (1%) between 1991 and
2002, and 86% of these were placed prophylactically.
Several reports exist in the literature on the use of
prophylactic VCFs in trauma patients with some of them
demonstrating a signiﬁcant reduction in the incidence of
PE. Khansarinia [94] found signiﬁcant diﬀerences in both
PE and PE-related death when compared high-risk trauma
patients with prophylactic Greenﬁeld ﬁlter placement with
injury-matched controls without ﬁlters. Velmahos and col-
legues [26] in their meta-analysis found that patients with
prophylactic vena cava ﬁlters had a lower incidence of PE
(0.2%) compared with those without ﬁlters (1.5%) versus
historical controls (5.8%). In a recent study by Toro et al.
[40], authors concluded that VCFs were safe and eﬀective
in preventing PE, and the risk of recurrent DVT was
low; however, some authors reported that permanent VCFs
had some disadvantages such as increasing the long-term
risk of DVT [95–97]. Phelan et al. [98] in a long-term
study regarding the follow-up of permanent VCF in trauma
patients, concluded that permanent ﬁlters should be the
choice for elderly patients. Since most of the trauma patients
are relativelyyounger,new solutionsmight berequired.With
the approval of retrievable systems, there has been renewed
interest in VCFs. The use of retrievable VCFs oﬀers a dual
advantage: ﬁrst protection against PE during the risk period,
and second the option of ﬁlter removal thus avoiding late
complications [96].
Some recent studies reported good results of retrievable
VCFs. Gorman et al. [97] using these ﬁlters in 113 trauma
patients concluded that retrievable ﬁlters were safe and
eﬀective in preventing PE in high-risk patients. Rosenthal
et al. [99] concluded that retrievable VCFs could even be
placed in bedside in ICU in critically ill trauma patients
and it was a safe and simple technique that was avoiding
the transportation of the patient out of ICU. Cherry et al.
[100] using the prophylactic retrievable VCFs in trauma
patients, reported 1.6% PE rate, high retrieval rate (59%),
low complication rate (0.1%), and satisfactory compliance
with traditional Eastern Association for the Surgery of
Trauma (EAST) guidelines.
8.What Do theLatestACCPand EAST
GuidelinesRecommendforDVTProphylaxis
inTrauma
For more than 20 years, American College of Chest Physi-
cians (ACCP) has published guidelines for the prevention
of VTE [101, 102]. According to the latest ACCP guide-
lines published in 2008 [101], ACCP recommends the use
of LMWH for major trauma patients as soon as it is
considered safe to do so. An acceptable alternative is the
combination of LMWH and the optimal use of a mechanical
method. If there is a contraindication for LMWHs, mechan-
ical thromboprophylaxis with PCD or possibly with GCS
alone was recommended. For major trauma patients with
impaired mobility, ACCP recommends thromboprophylaxis
until hospital discharge. ACCP recommends against the
use of a VCF as thromboprophylaxis for trauma and SCI
patients. For patients with acute SCI, ACCP recommends
thromboprophylaxis with LMWH, alternatively, combined
PCD and either LDH or LMWH. If anticoagulant therapy
is contraindicated, the optimal use of PCD and/or GCS is
recommended.
The Eastern Association for the Surgery of Trauma
(EAST) has taken a leadership role in the development of
evidenced-based guidelines for trauma [103]. a practice
management guidelines for the prevention of venous-
thromboembolism in trauma patients were published in July
2002 (Table 2)[ 50].
8.1. Recommendations of EAST about LDH. EAST group
has no Level I recommendation for LDH. As level II
recommendation, little evidence exist to support the beneﬁt
of LDH in the trauma patient. Level III recommendation is
thatforpatientsin whombleedingcouldworsen injuries, the
safety of LDH has not been established, and an individual
decision should be made when considering prophylaxis [50].
8.2. Recommendations of EAST about LMWH. EAST group
has no Level I recommendation for LMWH. According to
Level II recommendations LMWH can be used with the
following injury patterns:
(1) pelvic fractures (operative or prolonged bed rest),
(2) complex lower extremity fractures (operative or pro-
longed bed rest),
(3) spinal cord injury.
According to Level III recommendation, patients with an ISS
> 9 should receive LMWH primarily.
8.3. Recommendations of EAST about A-V Foot Pumps.
There is no Level I and Level II recommendation about
A-V foot pumps because of insuﬃcient data. According to
Level III recommendation, these devices may be used as a
substitute for pneumatic compression devices in those high-
risk trauma patients who cannot wear PCDs.
8.4. Recommendations of EAST about PCDs. There is no
Level I and Level II recommendation about PCDs because
of insuﬃcient data. According to Level III recommendation,
in the subset of head-injured patients, PCDs may have some
beneﬁt in isolated studies
8.5. Recommendations of EAST about VCFs. There is no
Level I and Level II recommendation about PCDs because
of insuﬃcient data. According to Level III recommendation,
insertion of a prophylactic VCF should be considered in
very-high-risk trauma patients who cannot receive antico-
agulation because of increased bleeding risk and have to be
immobilized for a long time [50].Thrombosis 7
Table 2: Recommendations of EAST group for the VTE prophylaxis in trauma patients.
Prophylaxis Level I recom. Level II recom. Level III recom.
LDH None Little evidence exist to support the
beneﬁt of LDH in the trauma patient
Individual decision should be made when
considering prophylaxis
LMWH None
(1) Pelvic fractures
(2) Complex lower extremity fractures
(3) Spinal cord injury.
Patients with an ISS > 9 should receive
LMWH primarily
A-V foot pump None None Substitude for PCDs in those high-risk
trauma patients who cannot wear PCDs
PCDs None None In head-injured patients, PCDs may have
some beneﬁt in isolated studies
VCFs None None Very-high-risk trauma patients who
cannot receive anticoagulation
9.Conclusions
It is clear that VTE is one of the major problems of trauma
patients. As demonstrated in the extended body of literature
on prophylaxis of VTE in trauma patients, there is an
insuﬃciency ofhigh-qualiﬁed clinicalstudiesto letclinicians
to decide the deﬁnite way for prophylaxis in this group
of patients. Despite the fact that none of the methods of
the prophylaxis provide complete prevention from VTE, it
is clear that without prophylaxis the incidence of occult
and nonoccult DVT would be higher with the potential for
increased risk of VTE-related morbidity and mortality.
Most recent clinical studies advocate the use of LMWHs
in the prevention of VTE in trauma patients; two important
guidelines, ACCP and EAST, also recommend primary use
of LMWHs in trauma patients. However, according to new
research we think that LDH may gain importance again
as it is shown that it might be as eﬀective as LMWHs in
traumapatientswithanadjustmentofdosageandthatmight
provide an advantage of lower costs. Larger and qualiﬁed
studies are required to be able to recommend the usage
of LDH again instead of LMWH. Mechanical prophylaxis
was also advocated by many studies and ACCP and EAST
guidelines; however it is mostly stated that this methods
should mostly be used as an adjuvant therapy to LMWHs
or they are recommended to be used where there is a
contraindication for LMWHs. Additionally the nature of the
major trauma itself can be a contraindication to use such
devices such as requirement for external ﬁxators on lower
extremities would prevent application of GCSs or PCDs.
There is increasing number of studies about VCFs.
Traditionally it is being used for PE prophylaxis where
there is a contraindication for LMWH prophylaxis; however
it is widely discussed that this device could be used for
primary prophylaxis in major trauma patients. Currently
EAST guidelines recommend the use of VCFs in very-high-
risk major trauma patients in case of a contraindication for
LMWHs. However, ACCP does not recommend the use of
VCFs in major trauma patients.
In conclusion, VTE prophylaxis in trauma patients is
necessary and with beneﬁt to the patient. The diminishment
of VTE with prophylaxis has not, however, completely
eliminated mortality or morbidity of VTE. Large qualiﬁed
randomized prospective clinical trials would be required to
diminish controversy and to further determine the ideal
prophylaxis for VTE in trauma patients.
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